RASSF2 and lung carcinoma: In this study, these treatments did not significantly influence in vitro cell survival with respect to the presence or absence of RASSF2 expression, in contrast to the positive effect of RASSF2 expression on the response to the regimen based on taxol and cisplatin in lung cancer [33].